What does CUSIP 92765F108 represent in this 13F holders report?

CUSIP 92765F108 is the security identifier for VIRX - Viracta Therapeutics, Inc. - Common Stock used to aggregate holder disclosures.

How many institutions held VIRX - Viracta Therapeutics, Inc. - Common Stock in Q2 2021?

57 institutional investors reported VIRX - Viracta Therapeutics, Inc. - Common Stock for Q2 2021. Use the holders table for investor-level position and value details.

Viracta Therapeutics, Inc. - Common Stock (VIRX)

CUSIP: 92765F108

Q2 2021 13F Holders as of 30 Jun 2021

Security type / class: Equity / Common Stock
Total 13F shares: 13,359,302
Total 13F value: $151,493,959
Share change: +3,431,059
Put/Call ratio: 155%
SEC-reported price per share: $11.34
Number of holders: 57
Value change: +$41,806,201
Number of buys: 38
Number of sells: 24
Shares outstanding: 19,711,628

Security key

92765F108

Report period

Q2 2021

Institutions

Top holders

VIRX full security history Ownership snapshot Full 13F holder table Viracta Therapeutics, Inc. SEC filings Viracta Therapeutics, Inc. company facts

Broader feeds

Latest 13F filings Latest 13D/G filings Investors directory

Ownership snapshot

Top reported holders of VIRX - Viracta Therapeutics, Inc. - Common Stock (13F + 13D/G + 3/4/5)

Grouped by holder across the latest SEC ownership disclosures. Start with comparable ownership when available, then verify the linked 13F, 13D/G, or 3/4/5 evidence.

Comparable stake leader

BVF INC/IL

Disclosed value leader

BVF INC/IL

Comparable rows

15/15

Latest evidence

31 Mar 2021

13F Lead comparable stake: 16% Showing 1-6 of 15 holder rows.

Quick read

BVF INC/IL leads the comparable SEC ownership view at 16%.

15 of 15 rows have a safely comparable ownership percentage. Use this as a filing-backed starting point, then open the detailed table for source links, reporting role, position value, share count, and filing date.

Open SEC evidence Opens BVF INC/IL's linked filing trail.

Comparable ownership Top 5

BVF INC/IL 16%

CITADEL ADVISORS LLC 7.7%

Samsara BioCapital, LLC 4.2%

SECTORAL ASSET MANAGEMENT INC 3.3%

Janus Henderson Group Ltd. 3.3%

Ownership % is shown only when SEC disclosures are safely comparable across share classes.

Detailed SEC evidence table Showing 1-6 of 15 holder rows

Holder	Evidence	Ownership %	Position	12M Net Δ	As of
BVF INC/IL	13F Company 13F	16%	$28,621,000 3,094,174 shares	—	31 Mar 2021
CITADEL ADVISORS LLC	13F Company 13F	7.7%	$14,093,000 1,523,512 shares	—	31 Mar 2021
Samsara BioCapital, LLC	13F Company 13F	4.2%	$7,693,000 831,625 shares	—	31 Mar 2021
SECTORAL ASSET MANAGEMENT INC	13F Company 13F	3.3%	$5,990,000 647,556 shares	—	31 Mar 2021
Janus Henderson Group Ltd.	13F Company 13F	3.3%	$5,990,000 646,820 shares	—	31 Mar 2021
GOLDMAN SACHS GROUP INC	13F Company 13F	3.1%	$5,587,000 603,974 shares	—	31 Mar 2021

How to read this table

Rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.

13F holder rows

Institutional holders as of Q2 2021

Investor-level positions for this CUSIP, loaded as an interactive table.

Institutions

13,359,302

Rows available

Investor	Option	Weight %	Change %	SEC-reported value	* Price	Shares	Share Change	Activity	Report Period

^* SEC-reported price is the security price as of the portfolio date and can indicate the last known price at which the security was still held. The marker flags a reported price that did not pass the local price check.

Compare Q2 2021 vs Q1 2021 Across Filers

Q1 2021 holders

Q2 2021 holders

Holder diff

Investor	Q1 2021 Shares	Q2 2021 Shares	Share Diff	Share Chg %	Q1 2021 value	Q2 2021 value	Value change	Value Chg %